Covers China healthcare and pharma market with digital platform & media, conferences & events, social network & community, and medical education & training
Palo Alto, Shanghai, Qingdao
Joined August 2020
- Tweets4.3K
- Following607
- Followers260
- Likes2.9K
At ESMO 2026, eChinaHealth interviewed Dr. Nathan Pennell, SVP and Global Head of Oncology Medical Affairs at BMS, on the global development strategy, clinical potential, and future of iza-bren (EGFR×HER3 #bispecific ADC).
Phase III #PANKU-Lung01 results: LBA71.
@bmsnews #ADC
1
46
At ESMO 2026 Madrid, eChinaHealth interviewed Prof. Li Zhang, lead PI of Phase III PANKU-Lung01, on iza-bren (EGFR×HER3 bispecific ADC) in EGFR-TKI-resistant NSCLC.
Median PFS: 11.1 vs 5.7 months (HR 0.40).
LBA71 | Published in The Lancet
#PANKI #EGFR #HER3 #LungCancer #ADC
1
48
How can China’s positive clinical data accelerate global drug development?
At ESMO26 Madrid, eChinaHealth interviewed Dr. Dimitrios Zardavas of BMS on the global development of iza-bren, indication prioritization, and challenges in a rapidly evolving oncology landscape.
@bmsnews
1
35
Could iza-bren reshape treatment beyond HER2-based selection?
At ESMO 26 Madrid, eChinaHealth interviewed Prof. Bo Lan, first author of Phase III PANKU-Breast01, on the #EGFR × #HER3 #bispecific #ADC and its clinical impact.
LBA50 | Published in The #Lancet
#BreastCancer #ADC
26
eChinaHealth interviewed Prof. Binghe Xu, lead PI of PANKU-Breast01, at ESMO 2026 Madrid on iza-bren (EGFR×HER3 bispecific ADC) and its potential in HR+/HER2− breast cancer.
Phase III results were presented as LBA50 and published in The #Lancet.
#iza #bren #ADC #breastcancer
36
Published by CACA and Tianjin Medical University, Cancer Biology & Medicine focuses on advancing translational cancer research. The journal is indexed in SCIE (IF=12.4), MEDLINE, and SCOPUS (CiteScore=11.5).
Click below to view the content of Issue 10.
cancerbiomed.org/content/23/…
39
12,493 Chinese physicians joined virtually for “Scientific Dialogue – #OptiTROP-Lung06 Study” recorded in Madrid studio and broadcast after ESMO26. Many thanks to our outstanding speakers for sharing their insights.
@HwakeleeMD @fred_hirsch @StephenVLiu @FedericoCappuz1 #NSCLC
13,316 Chinese physicians joined virtually for “Lung Cancer Scientific Dialogue – OptiTROP-Lung04 Study” recorded in Madrid studio and broadcast after ESMO26. Many thanks to our outstanding speakers for sharing their expertise and insights.
@unito #OptiTROP #Lungcaner #NSCLC
1
48
A full house of in-person attendees at our “Gastric Cancer Dialogue: CLARITY GASTRIC-01 Study” scientific roundtable in Madrid during ESMO26!
Many thanks to our outstanding speakers and all attendees for making this an engaging and insightful discussion.
@KoheiShitara
#gastric
16,587 Chinese physicians joined virtually for “Bispecific ADC in Lung Cancer: PANKU-Lung01” recorded in Madrid studio and broadcast after ESMO 2026. Many thanks to our outstanding speakers for sharing insights.
@dplanchard @FordePatrick @bmsnews
#lungcancer #Bispecific #ADC
1
56
12,323 Chinese physicians joined virtually for “Scientific Roundtable: DeLLphi-305 Study” recorded in Madrid studio and broadcast after ESMO 2026. Many thanks to our outstanding speakers for sharing their expertise and insights.
@sands_jacob @Alfdoc2
#DeLLphi305 #DeLLphi #SCLC
19,162 Chinese physicians joined virtually for “Bispecific ADC in Breast Cancer: PANKU-Breast01” recorded in Madrid studio and broadcast after ESMO 2026. Many thanks to our outstanding speakers for sharing their insights.
@ValenzaCarmine @DFCI_BreastOnc @IEOufficiale @bmsnews
1
61
10,728 Chinese physicians joined virtually for “Scientific Roundtable: Advances in Perioperative Immunotherapy” recorded in Madrid and broadcast after ESMO26. Many thanks to our outstanding speakers for sharing their insights.
@t_mitsudomi @FordePatrick
#Perioperative #Lung
1
39
11,804 Chinese physicians joined virtually for “MASTER TALK: ALINA Study” recorded in Madrid studio and broadcast after ESMO 2026. Many thanks to our outstanding speakers for sharing their expertise and insights.
@ThomasW35874311 #Alectinib #Alecensa #NSCLC #ALKpositive
1
52
Bispecific ADC — A New Chapter in Oncology on Lung Cancer
📅 Oct 30 | 7–8 PM China / 7–8 AM US ET
🎥 Expert discussions recorded in Madrid, broadcast via Zoom
🌐 English + live Chinese interpretation
🎟️ Free registration: bit.ly/4squ2Pp
#lungcancer #Bispecific #ADC
Bispecific ADC - A New Chapter in Oncology on Breast Cancer
📅 Oct 29 | 7–8 PM China / 7–8 AM US ET
🎥 Expert discussions recorded in Madrid, broadcast via Zoom
🌐 English + live Chinese interpretation
🎟️ Registration: bit.ly/4ifdZPG
#Bispecific #ADC #BreastCancer
1
63
SANOVO: Pioneering Dual-Targeted Therapy in 1L EGFRm & MET OE NSCLC
📅 Oct 29 | 6–7 PM China / 8–9 AM US ET
🎥 Expert discussions recorded in Madrid, broadcast via Zoom
🌐 English + live Chinese interpretation
🎟️ Free registration: bit.ly/4eUtCuR
#SANOVO #EGFR #MET
1
58
Agenda
Chairperson Opening Remarks & SANOVO Results Recap
- Prof. Yi-Long Wu, Guangdong Provincial People's Hospital
@ThomasW35874311
1
16